Amgen (1AMGN) Stock Price & Analysis
1AMGN Stock Chart & Stats
- Day’s Range
- EUR 421.15 - EUR 426.00
- 52-Week Range
- EUR 249.30 - EUR 569.00
- Previous Close
- EUR 411.55
- Volume
- 5
- Average Volume (3M)
- 50
- Market Cap
- EUR 224.83B
- Enterprise Value
- EUR 240.31B
- Total Cash (Recent Filing)
- EUR 13.99B
- Total Debt (Recent Filing)
- EUR 57.30B
- Price to Earnings (P/E)
- 28.7
- Beta
- 0.15
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 5.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.01%
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Growth
Broad growth across major products reduces reliance on a single therapy and shows that Amgen’s commercial momentum is supported by a diversified portfolio. Continued expansion across multiple franchises can improve revenue durability and help offset individual product maturation.
Strong Cash Generation
Amgen converts its profitable operations into substantial operating and free cash flow, providing resources for research, manufacturing investment, dividends, and business development. Strong cash generation also offers meaningful support for managing obligations despite the company’s elevated leverage.
Pipeline Expansion
Positive Phase 3 data for dazodalibep expands the potential commercial pipeline beyond Amgen’s established franchises. If supported by regulatory progress, the asset could add a new growth opportunity and strengthen longer-term portfolio diversification in autoimmune disease.
Bears Say
High Leverage
Amgen’s sizable debt burden reduces financial flexibility and makes the business more sensitive to refinancing costs or a downturn in earnings. Although leverage has improved from prior years, obligations remain high relative to equity and could constrain future capital allocation.
Biosimilar Erosion
The decline in Prolia and XGEVA demonstrates how biosimilar competition can materially erode established biologic revenue. Continued pressure on these franchises may offset growth from newer products and require successful launches or indications to sustain portfolio-wide expansion.
Regulatory Compliance Risk
The FDA’s finding creates a durable compliance and reputational risk around promotion of a marketed oncology product. Required corrective action, and the possibility of legal measures if violations are not addressed, could increase oversight and complicate commercial execution.
Amgen News
1AMGN FAQ
What was Amgen’s price range in the past 12 months?
What is Amgen’s market cap?
When is Amgen’s upcoming earnings report date?
How were Amgen’s earnings last quarter?
Is Amgen overvalued?
Does Amgen pay dividends?
What is Amgen’s EPS estimate?
How many shares outstanding does Amgen have?
What happened to Amgen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Amgen?
What is the TipRanks Smart Score and how is it calculated?
Amgen Stock Smart Score
Company Description
Amgen
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Bradway
- Employees
- 31,500
- Website
- www.amgen.com
- Address
- One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, US
Amgen (1AMGN) Earnings & Revenues
1AMGN Company Deck
1AMGN Earnings Call
Earnings Call SentimentPositive
The call reported broad-based commercial strength (10% revenue growth, multiple products with double-digit increases, raised full-year guidance), robust margins (48% non-GAAP operating margin) and strong cash generation, while also flagging expected near-term expense increases, higher cost-of-sales pressure from mix and profit-share, a material decline in the Prolia/XGEVA franchise (–33%), and some pipeline uncertainty/readouts pending. On balance the positive commercial execution, raised guidance and pipeline momentum outweigh the noted headwinds.
View all IT:1AMGN earnings summaries1AMGN Net sales Breakdown
- 13.09% Prolia
- 9.92% Enbrel
- 6.66% XGEVA
- 6.65% Repatha
- 63.69% Other
1AMGN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 0 | 7 |
| Technical Analysis | 3 | 0 | 7 |
| Moving Averages | 12 | 0 | 0 |